Citigroup
LABU icon

Citigroup’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Citigroup’s Portfolio LABU Stock Details LABU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$159 – 6181
2025
Q4 		$159 Sell
1
-278
-100% -$38.2K ﹤0.01% 5648
2025
Q3 		$26.1K Buy
+279
New +$19.7K ﹤0.01% 4727
2025
Q1 		– Sell
-794
Closed -$71.5K – 5787
2024
Q4 		$71.5K Hold
794
– – ﹤0.01% 4970
2024
Q3 		$102K Sell
794
-315
-28% -$41.1K ﹤0.01% 4751
2024
Q2 		$126K Sell
1,109
-200
-15% -$21.4K ﹤0.01% 4105
2024
Q1 		$174K Sell
1,309
-111
-8% -$14.5K ﹤0.01% 4080
2023
Q4 		$173K Sell
1,420
-151
-10% -$11.6K ﹤0.01% 3976
2023
Q3 		$120K Sell
1,571
-370
-19% -$38K ﹤0.01% 3867
2023
Q2 		$230K Buy
1,941
+710
+58% +$88.5K ﹤0.01% 3827
2023
Q1 		$121K Sell
1,231
-210
-15% -$28.5K ﹤0.01% 3949
2022
Q4 		$204K Buy
1,441
+855
+146% +$119K ﹤0.01% 3711
2022
Q3 		$82K Sell
586
-1,114
-66% -$204K ﹤0.01% 4182
2022
Q2 		$229K Buy
1,700
+550
+48% +$93.7K ﹤0.01% 3770
2022
Q1 		$361K Buy
1,150
+940
+448% +$354K ﹤0.01% 3726
2021
Q4 		$151K Buy
210
+195
+1,300% +$187K ﹤0.01% 4510
2021
Q3 		$17K Hold
15
– – ﹤0.01% 5291
2021
Q2 		$22K Hold
15
– – ﹤0.01% 5247
2021
Q1 		$24K Buy
+15
New +$35.1K ﹤0.01% 5141
2020
Q2 		– Sell
-5,491
Closed -$4.76M – 7612
2020
Q1 		$2.48M Buy
5,491
+5,452
+13,979% +$4.96M ﹤0.01% 2284
2019
Q4 		$45K Sell
39
-4,976
-99% -$4.46M ﹤0.01% 6390
2019
Q3 		$3.1M Buy
5,015
+3,265
+187% +$2.71M ﹤0.01% 2383
2019
Q2 		$1.76M Buy
1,750
+1,406
+409% +$1.36M ﹤0.01% 3015
2019
Q1 		$413K Sell
344
-1,113
-76% -$1.16M ﹤0.01% 4383
2018
Q4 		$958K Buy
1,457
+1,251
+607% +$1.31M ﹤0.01% 3454
2018
Q3 		$382K Buy
206
+40
+24% +$78.6K ﹤0.01% 4597
2018
Q2 		$314K Buy
166
+55
+50% +$96.9K ﹤0.01% 4585
2018
Q1 		$175K Buy
111
+105
+1,750% +$195K ﹤0.01% 5096
2017
Q4 		$10K Sell
6
-7,494
-100% -$11.5M ﹤0.01% 7042
2017
Q3 		$12.8M Sell
7,500
-2,500
-25% -$3.47M 0.01% 1073
2017
Q2 		$12.6M Buy
+10,000
New +$10.1M 0.01% 994
2016
Q2 		– Sell
-13
Closed -$7K – 7241
2016
Q1 		$7K Buy
+13
New +$8.22K ﹤0.01% 6907
2015
Q3 		– Sell
-525
Closed -$2M – 7545
2015
Q2 		$2M Buy
+525
New +$1.86M ﹤0.01% 2512

Other funds holding LABU

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
MIG
McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return
Belvedere Trading
Belvedere Trading Chicago, Illinois $84.4B AUM 52.68% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Citigroup's LABU Position: Q1 2026 in Review

Citigroup sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q1 2026, closing a stake of 1 share — an estimated $159 sold.

Citigroup first reported a position in LABU in Q2 2015 and held it in 32 quarters. The position peaked at $12.8M in Q3 2017. 33 funds tracked by Wall St. Rank hold LABU as of Q1 2026.

  • Citigroup reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 1 Direxion Daily S&P Biotech Bull 3X ETF share in Q1 2026, an estimated $159.
  • Citigroup first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q2 2015 and held it in 32 quarters.
  • Citigroup's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $12.8M in Q3 2017.
  • 33 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.